- Details
- (Length of Conversation: 16 min) Matthew Cooperberg and Charles Ryan discuss active surveillance in the low risk and low volume disease setting. Topics include defining the appropriate patient for active surveillance in 2018 and reaching a global consensus, how much age factors into active surveillance, how biomarkers and imaging are driving research and decision making in the active surveillance...
|
- Details
- (Length of Discussion: 11 min) Silke Gillessen, in conversation with Alicia Morgans provides an overview of many of the changes we are experiencing in clinical practice since the 2017 APCCC. They touch upon the new data that is driving change in clinical practice and some unanswered questions that have arisen and will be discussed in the upcoming 2019 Advanced Prostate Cancer Consensus Conference...
|
- Details
- (Length of Interview: 15 min) Badrinath Konety and Alicia Morgans discuss biomarker in bladder cancer. Concepts discussed include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. Biographies: Badrinath Konety, MD, MBA , is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncol...
|
- Details
- (Length of Discussion: 11 min) Karim Fizazi and Alicia Morgans discuss various treatment data in the metastatic hormone sensitive space, including LATITUDE, CHAARTED and STAMPEDE trials. Dr. Fizazi describes the European Consortium PEACE trials designed for the current generation of prostate and advance prostate cancer patients. The Prostate Cancer Consortium in Europe (PEACE) was established in 2...
|
- Details
- (Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...
|
- Details
- (Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...
|
- Details
- (Length of conversation: 11 min) Cora Sternberg, MD and Alicia Morgans, MD explore the importance of the study results from Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) . The purpose of this study was to assess the safety and efficacy of enzalutamide in patients with non metastatic (M0) prostate cancer. Dr. Sternberg discus...
|
- Details
- (Length of Discussion: 22 min) Alicia Morgans and Maha Hussain discuss the Evaluating the Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) phase III randomized double-blind controlled trial , in the nonmetastatic castration-resistant prostate cancer (nmCRPC) patient population which was first presented at the 2018 ASCO GU meeti...
|
- Details
- (Length of Discussion: 7 min) Dr. Thomas Keane reviews the first presentation on the PROSPER study which was a much awaited presentation presented by Dr. Maha Hussain at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Dr. Hussain started her presentation on PROSPER, a phase III randomized double-blind controlled trial, Safety and Efficacy Study of...
|
